10-Q Filing
Filing Information
| Form Type | 10-Q |
| Accession Number | 0001552781-21-000810 |
| Period End Date | 20210930 |
| Filing Date | 20211112 |
| Fiscal Year | 2021 |
| Fiscal Period | Q3 |
| XBRL Instance | e21622_swkh-10q_htm.xml |
Filing Contents
This filing contains the following financial statements:
Balance Sheet
78 line items
| Line Item | Tag | Value | Unit | Period |
|---|---|---|---|---|
| Preferred Stock, Par Value |
PreferredStockParOrStatedValuePerShare
|
$0.00 | USD | Point-in-time |
| Preferred Stock, Par Value |
PreferredStockParOrStatedValuePerShare
|
$0.00 | USD | Point-in-time |
| Preferred Stock, Shares Authorized |
PreferredStockSharesAuthorized
|
5.00M | shares | Point-in-time |
| Preferred Stock, Shares Authorized |
PreferredStockSharesAuthorized
|
5.00M | shares | Point-in-time |
| Cash and cash equivalents |
CashAndCashEquivalentsAtCarryingValue
|
$9.31M | USD | Point-in-time |
| Preferred Stock, Shares Issued |
PreferredStockSharesIssued
|
0.00 | shares | Point-in-time |
| Cash and cash equivalents |
CashAndCashEquivalentsAtCarryingValue
|
$3.01M | USD | Point-in-time |
| Preferred Stock, Shares Issued |
PreferredStockSharesIssued
|
0.00 | shares | Point-in-time |
| Cash and cash equivalents |
CashAndCashEquivalentsAtCarryingValue
|
$11.16M | USD | Point-in-time |
| Cash and cash equivalents |
CashAndCashEquivalentsAtCarryingValue
|
$18.64M | USD | Point-in-time |
| Preferred Stock, Shares Outstanding |
PreferredStockSharesOutstanding
|
0.00 | shares | Point-in-time |
| Preferred Stock, Shares Outstanding |
PreferredStockSharesOutstanding
|
0.00 | shares | Point-in-time |
| Interest and accounts receivable, net |
AccountsReceivableNet
|
$2.25M | USD | Point-in-time |
| Interest and accounts receivable, net |
AccountsReceivableNet
|
$1.91M | USD | Point-in-time |
| Marketable investments |
MarketableSecurities
|
$2.77M | USD | Point-in-time |
| Marketable investments |
MarketableSecurities
|
$1.21M | USD | Point-in-time |
| Common Stock, Par Value |
CommonStockParOrStatedValuePerShare
|
$0.00 | USD | Point-in-time |
| Common Stock, Par Value |
CommonStockParOrStatedValuePerShare
|
$0.00 | USD | Point-in-time |
| Common Stock, Shares Authorized |
CommonStockSharesAuthorized
|
250.00M | shares | Point-in-time |
| Common Stock, Shares Authorized |
CommonStockSharesAuthorized
|
250.00M | shares | Point-in-time |
| Other current assets |
OtherAssetsCurrent
|
$542.00K | USD | Point-in-time |
| Other current assets |
OtherAssetsCurrent
|
$1.10M | USD | Point-in-time |
| Common Stock, Shares, Issued |
CommonStockSharesIssued
|
12.80M | shares | Point-in-time |
| Total current assets |
AssetsCurrent
|
$24.76M | USD | Point-in-time |
| Common Stock, Shares, Issued |
CommonStockSharesIssued
|
12.79M | shares | Point-in-time |
| Total current assets |
AssetsCurrent
|
$6.67M | USD | Point-in-time |
| Common Stock, Shares, Outstanding |
CommonStockSharesOutstanding
|
12.80M | shares | Point-in-time |
| Common Stock, Shares, Outstanding |
CommonStockSharesOutstanding
|
12.79M | shares | Point-in-time |
| Finance receivables, net |
NotesAndLoansReceivableNetCurrent
|
$196.14M | USD | Point-in-time |
| Finance receivables, net |
NotesAndLoansReceivableNetCurrent
|
$204.49M | USD | Point-in-time |
| Marketable investments |
AvailableForSaleSecuritiesDebtSecurities
|
$241.00K | USD | Point-in-time |
| Marketable investments |
AvailableForSaleSecuritiesDebtSecurities
|
$198.00K | USD | Point-in-time |
| Cost method investment |
CostMethodInvestments
|
$3.49M | USD | Point-in-time |
| Cost method investment |
CostMethodInvestments
|
$3.49M | USD | Point-in-time |
| Deferred tax assets, net |
DeferredIncomeTaxAssetsNet
|
$22.65M | USD | Point-in-time |
| Deferred tax assets, net |
DeferredIncomeTaxAssetsNet
|
$27.49M | USD | Point-in-time |
| Warrant assets |
WarrantAssets
|
$2.97M | USD | Point-in-time |
| Warrant assets |
WarrantAssets
|
$3.65M | USD | Point-in-time |
| Intangible assets, net |
IntangibleAssetsNetExcludingGoodwill
|
$13.62M | USD | Point-in-time |
| Intangible assets, net |
IntangibleAssetsNetExcludingGoodwill
|
$10.51M | USD | Point-in-time |
| Goodwill |
Goodwill
|
$8.40M | USD | Point-in-time |
| Goodwill |
Goodwill
|
$8.40M | USD | Point-in-time |
| Property and equipment, net |
PropertyPlantAndEquipmentNet
|
$5.79M | USD | Point-in-time |
| Property and equipment, net |
PropertyPlantAndEquipmentNet
|
$5.21M | USD | Point-in-time |
| Other non-current assets |
OtherAssetsNoncurrent
|
$1.03M | USD | Point-in-time |
| Other non-current assets |
OtherAssetsNoncurrent
|
$1.31M | USD | Point-in-time |
| Total assets |
Assets
|
$276.62M | USD | Point-in-time |
| Total assets |
Assets
|
$273.90M | USD | Point-in-time |
| Accounts payable and accrued liabilities |
AccountsPayableAndAccruedLiabilitiesCurrent
|
$3.65M | USD | Point-in-time |
| Accounts payable and accrued liabilities |
AccountsPayableAndAccruedLiabilitiesCurrent
|
$4.49M | USD | Point-in-time |
| Revolving credit facility |
LinesOfCreditCurrent
|
$8.00K | USD | Point-in-time |
| Revolving credit facility |
LinesOfCreditCurrent
|
$11.76M | USD | Point-in-time |
| Total current liabilities |
LiabilitiesCurrent
|
$15.41M | USD | Point-in-time |
| Total current liabilities |
LiabilitiesCurrent
|
$4.50M | USD | Point-in-time |
| Contingent consideration payable |
ContingentConsiderationPayable
|
$10.67M | USD | Point-in-time |
| Contingent consideration payable |
ContingentConsiderationPayable
|
$16.90M | USD | Point-in-time |
| Other non-current liabilities |
OtherLiabilitiesNoncurrent
|
$1.08M | USD | Point-in-time |
| Other non-current liabilities |
OtherLiabilitiesNoncurrent
|
$779.00K | USD | Point-in-time |
| Total liabilities |
Liabilities
|
$15.95M | USD | Point-in-time |
| Total liabilities |
Liabilities
|
$33.39M | USD | Point-in-time |
| Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively |
PreferredStockValue
|
- | USD | Point-in-time |
| Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively |
PreferredStockValue
|
- | USD | Point-in-time |
| Common stock, $0.001 par value; 250,000,000 shares authorized; 12,801,313 and 12,792,586 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively |
CommonStockValue
|
$13.00K | USD | Point-in-time |
| Common stock, $0.001 par value; 250,000,000 shares authorized; 12,801,313 and 12,792,586 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively |
CommonStockValue
|
$13.00K | USD | Point-in-time |
| Additional paid-in capital |
AdditionalPaidInCapital
|
$4.43B | USD | Point-in-time |
| Additional paid-in capital |
AdditionalPaidInCapital
|
$4.43B | USD | Point-in-time |
| Accumulated deficit |
RetainedEarningsAccumulatedDeficit
|
$-4.17B | USD | Point-in-time |
| Accumulated deficit |
RetainedEarningsAccumulatedDeficit
|
$-4.19B | USD | Point-in-time |
| Total stockholders equity |
StockholdersEquity
|
$240.51M | USD | Point-in-time |
| Total stockholders equity |
StockholdersEquity
|
$258.24M | USD | Point-in-time |
| Total stockholders equity |
StockholdersEquity
|
$232.08M | USD | Point-in-time |
| Total stockholders equity |
StockholdersEquity
|
$260.67M | USD | Point-in-time |
| Total stockholders equity |
StockholdersEquity
|
$235.70M | USD | Point-in-time |
| Total stockholders equity |
StockholdersEquity
|
$244.08M | USD | Point-in-time |
| Total stockholders equity |
StockholdersEquity
|
$232.00M | USD | Point-in-time |
| Total stockholders equity |
StockholdersEquity
|
$236.53M | USD | Point-in-time |
| Total liabilities and stockholders equity |
LiabilitiesAndStockholdersEquity
|
$276.62M | USD | Point-in-time |
| Total liabilities and stockholders equity |
LiabilitiesAndStockholdersEquity
|
$273.90M | USD | Point-in-time |
Income Statement
84 line items
| Line Item | Tag | Value | Unit | Period |
|---|---|---|---|---|
| Finance receivables interest income, including fees |
InterestAndFeeIncomeLoansAndLeases
|
$22.74M | USD | 3 Qtrs |
| Finance receivables interest income, including fees |
InterestAndFeeIncomeLoansAndLeases
|
$9.37M | USD | 1 Quarter |
| Finance receivables interest income, including fees |
InterestAndFeeIncomeLoansAndLeases
|
$7.87M | USD | 1 Quarter |
| Finance receivables interest income, including fees |
InterestAndFeeIncomeLoansAndLeases
|
$29.86M | USD | 3 Qtrs |
| Pharmaceutical development |
PharmaceuticalDevelopmentRevenue
|
$3.08M | USD | 3 Qtrs |
| Pharmaceutical development |
PharmaceuticalDevelopmentRevenue
|
$10.85M | USD | 3 Qtrs |
| Pharmaceutical development |
PharmaceuticalDevelopmentRevenue
|
$2.78M | USD | 1 Quarter |
| Pharmaceutical development |
PharmaceuticalDevelopmentRevenue
|
$187.00K | USD | 1 Quarter |
| Other |
RevenueNotFromContractWithCustomerOther
|
- | USD | 1 Quarter |
| Other |
RevenueNotFromContractWithCustomerOther
|
$496.00K | USD | 3 Qtrs |
| Other |
RevenueNotFromContractWithCustomerOther
|
$9.00K | USD | 3 Qtrs |
| Other |
RevenueNotFromContractWithCustomerOther
|
- | USD | 1 Quarter |
| Total revenues |
Revenues
|
$41.20M | USD | 3 Qtrs |
| Total revenues |
Revenues
|
$25.82M | USD | 3 Qtrs |
| Total revenues |
Revenues
|
$9.56M | USD | 1 Quarter |
| Total revenues |
Revenues
|
$10.65M | USD | 1 Quarter |
| Impairment expense |
OperatingLeaseImpairmentLoss
|
- | USD | 1 Quarter |
| Impairment expense |
OperatingLeaseImpairmentLoss
|
$163.00K | USD | 3 Qtrs |
| Impairment expense |
OperatingLeaseImpairmentLoss
|
- | USD | 1 Quarter |
| Impairment expense |
OperatingLeaseImpairmentLoss
|
- | USD | 3 Qtrs |
| Interest expense |
InterestExpense
|
$365.00K | USD | 3 Qtrs |
| Interest expense |
InterestExpense
|
$101.00K | USD | 1 Quarter |
| Interest expense |
InterestExpense
|
$292.00K | USD | 3 Qtrs |
| Interest expense |
InterestExpense
|
$53.00K | USD | 1 Quarter |
| Pharmaceutical manufacturing, research and development expense |
ResearchAndDevelopmentExpense
|
$1.18M | USD | 1 Quarter |
| Pharmaceutical manufacturing, research and development expense |
ResearchAndDevelopmentExpense
|
$3.31M | USD | 3 Qtrs |
| Pharmaceutical manufacturing, research and development expense |
ResearchAndDevelopmentExpense
|
$2.49M | USD | 1 Quarter |
| Pharmaceutical manufacturing, research and development expense |
ResearchAndDevelopmentExpense
|
$5.58M | USD | 3 Qtrs |
| Change in fair value of acquisition-related contingent consideration |
ChangeInFairValueOfAcquisitionrelatedContingentConsideration
|
- | USD | 1 Quarter |
| Change in fair value of acquisition-related contingent consideration |
ChangeInFairValueOfAcquisitionrelatedContingentConsideration
|
$1.96M | USD | 3 Qtrs |
| Change in fair value of acquisition-related contingent consideration |
ChangeInFairValueOfAcquisitionrelatedContingentConsideration
|
$-147.00K | USD | 3 Qtrs |
| Change in fair value of acquisition-related contingent consideration |
ChangeInFairValueOfAcquisitionrelatedContingentConsideration
|
$174.00K | USD | 1 Quarter |
| Depreciation and amortization expense |
DepreciationAndAmortization
|
$2.68M | USD | 1 Quarter |
| Depreciation and amortization expense |
DepreciationAndAmortization
|
$3.31M | USD | 3 Qtrs |
| Depreciation and amortization expense |
DepreciationAndAmortization
|
$812.00K | USD | 1 Quarter |
| Depreciation and amortization expense |
DepreciationAndAmortization
|
$9.63M | USD | 3 Qtrs |
| General and administrative |
GeneralAndAdministrativeExpense
|
$8.21M | USD | 3 Qtrs |
| General and administrative |
GeneralAndAdministrativeExpense
|
$9.82M | USD | 3 Qtrs |
| General and administrative |
GeneralAndAdministrativeExpense
|
$2.53M | USD | 1 Quarter |
| General and administrative |
GeneralAndAdministrativeExpense
|
$3.58M | USD | 1 Quarter |
| Total costs and expenses |
CostsAndExpenses
|
$23.65M | USD | 3 Qtrs |
| Total costs and expenses |
CostsAndExpenses
|
$18.85M | USD | 3 Qtrs |
| Total costs and expenses |
CostsAndExpenses
|
$6.93M | USD | 1 Quarter |
| Total costs and expenses |
CostsAndExpenses
|
$6.67M | USD | 1 Quarter |
| Unrealized net (loss) gain on warrants |
UnrealizedGainLossOnDerivatives
|
$-214.00K | USD | 1 Quarter |
| Unrealized net (loss) gain on warrants |
UnrealizedGainLossOnDerivatives
|
$678.00K | USD | 3 Qtrs |
| Unrealized net (loss) gain on warrants |
UnrealizedGainLossOnDerivatives
|
$-1.15M | USD | 3 Qtrs |
| Unrealized net (loss) gain on warrants |
UnrealizedGainLossOnDerivatives
|
$87.00K | USD | 1 Quarter |
| Unrealized net gain (loss) on equity securities |
MarketableSecuritiesUnrealizedGainLoss
|
$1.56M | USD | 3 Qtrs |
| Unrealized net gain (loss) on equity securities |
MarketableSecuritiesUnrealizedGainLoss
|
$342.00K | USD | 1 Quarter |
| Unrealized net gain (loss) on equity securities |
MarketableSecuritiesUnrealizedGainLoss
|
$-178.00K | USD | 1 Quarter |
| Unrealized net gain (loss) on equity securities |
MarketableSecuritiesUnrealizedGainLoss
|
$-666.00K | USD | 3 Qtrs |
| Income before income tax expense (benefit) |
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
$2.76M | USD | 1 Quarter |
| Income before income tax expense (benefit) |
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
$359.00K | USD | 3 Qtrs |
| Income before income tax expense (benefit) |
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
$24.58M | USD | 3 Qtrs |
| Income before income tax expense (benefit) |
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
$3.89M | USD | 1 Quarter |
| Income tax expense (benefit) |
IncomeTaxExpenseBenefit
|
$-451.00K | USD | 1 Quarter |
| Income tax expense (benefit) |
IncomeTaxExpenseBenefit
|
$4.98M | USD | 3 Qtrs |
| Income tax expense (benefit) |
IncomeTaxExpenseBenefit
|
$-199.00K | USD | 3 Qtrs |
| Income tax expense (benefit) |
IncomeTaxExpenseBenefit
|
$513.00K | USD | 1 Quarter |
| Consolidated net income |
ProfitLoss
|
$13.97M | USD | 1 Quarter |
| Consolidated net income |
ProfitLoss
|
$2.24M | USD | 1 Quarter |
| Consolidated net income |
ProfitLoss
|
$558.00K | USD | 3 Qtrs |
| Consolidated net income |
ProfitLoss
|
$-4.66M | USD | 1 Quarter |
| Consolidated net income |
ProfitLoss
|
$876.00K | USD | 1 Quarter |
| Consolidated net income |
ProfitLoss
|
$3.39M | USD | 1 Quarter |
| Consolidated net income |
ProfitLoss
|
$19.60M | USD | 3 Qtrs |
| Consolidated net income |
ProfitLoss
|
$4.34M | USD | 1 Quarter |
| Basic |
EarningsPerShareBasic
|
$0.34 | USD | 1 Quarter |
| Basic |
EarningsPerShareBasic
|
$0.18 | USD | 1 Quarter |
| Basic |
EarningsPerShareBasic
|
$1.53 | USD | 3 Qtrs |
| Basic |
EarningsPerShareBasic
|
$0.04 | USD | 3 Qtrs |
| Diluted |
EarningsPerShareDiluted
|
$1.53 | USD | 3 Qtrs |
| Diluted |
EarningsPerShareDiluted
|
$0.17 | USD | 1 Quarter |
| Diluted |
EarningsPerShareDiluted
|
$0.04 | USD | 3 Qtrs |
| Diluted |
EarningsPerShareDiluted
|
$0.34 | USD | 1 Quarter |
| Basic |
WeightedAverageNumberOfSharesOutstandingBasic
|
12.90M | shares | 1 Quarter |
| Basic |
WeightedAverageNumberOfSharesOutstandingBasic
|
12.89M | shares | 3 Qtrs |
| Basic |
WeightedAverageNumberOfSharesOutstandingBasic
|
12.80M | shares | 3 Qtrs |
| Basic |
WeightedAverageNumberOfSharesOutstandingBasic
|
12.80M | shares | 1 Quarter |
| Diluted |
WeightedAverageNumberOfDilutedSharesOutstanding
|
12.83M | shares | 3 Qtrs |
| Diluted |
WeightedAverageNumberOfDilutedSharesOutstanding
|
12.92M | shares | 1 Quarter |
| Diluted |
WeightedAverageNumberOfDilutedSharesOutstanding
|
12.86M | shares | 1 Quarter |
| Diluted |
WeightedAverageNumberOfDilutedSharesOutstanding
|
12.90M | shares | 3 Qtrs |
Cash Flow Statement
78 line items
| Line Item | Tag | Value | Unit | Period |
|---|---|---|---|---|
| Consolidated net income |
ProfitLoss
|
$13.97M | USD | 1 Quarter |
| Consolidated net income |
ProfitLoss
|
$2.24M | USD | 1 Quarter |
| Consolidated net income |
ProfitLoss
|
$558.00K | USD | 3 Qtrs |
| Consolidated net income |
ProfitLoss
|
$-4.66M | USD | 1 Quarter |
| Consolidated net income |
ProfitLoss
|
$876.00K | USD | 1 Quarter |
| Consolidated net income |
ProfitLoss
|
$3.39M | USD | 1 Quarter |
| Consolidated net income |
ProfitLoss
|
$19.60M | USD | 3 Qtrs |
| Consolidated net income |
ProfitLoss
|
$4.34M | USD | 1 Quarter |
| Impairment expense |
OperatingLeaseImpairmentLoss
|
- | USD | 1 Quarter |
| Impairment expense |
OperatingLeaseImpairmentLoss
|
$163.00K | USD | 3 Qtrs |
| Impairment expense |
OperatingLeaseImpairmentLoss
|
- | USD | 1 Quarter |
| Impairment expense |
OperatingLeaseImpairmentLoss
|
- | USD | 3 Qtrs |
| Amortization of debt issuance costs |
AmortizationOfFinancingCosts
|
$141.00K | USD | 3 Qtrs |
| Amortization of debt issuance costs |
AmortizationOfFinancingCosts
|
$35.00K | USD | 3 Qtrs |
| Deferred income taxes |
DeferredIncomeTaxesAndTaxCredits
|
$4.84M | USD | 3 Qtrs |
| Deferred income taxes |
DeferredIncomeTaxesAndTaxCredits
|
$-206.00K | USD | 3 Qtrs |
| Change in fair value of warrants |
FairValueAdjustmentOfWarrants
|
$1.15M | USD | 3 Qtrs |
| Change in fair value of warrants |
FairValueAdjustmentOfWarrants
|
$-678.00K | USD | 3 Qtrs |
| Change in fair value of equity securities |
MarketableSecuritiesUnrealizedGainLoss
|
$1.56M | USD | 3 Qtrs |
| Change in fair value of equity securities |
MarketableSecuritiesUnrealizedGainLoss
|
$342.00K | USD | 1 Quarter |
| Change in fair value of equity securities |
MarketableSecuritiesUnrealizedGainLoss
|
$-178.00K | USD | 1 Quarter |
| Change in fair value of equity securities |
MarketableSecuritiesUnrealizedGainLoss
|
$-666.00K | USD | 3 Qtrs |
| Change in fair value of acquisition-related contingent consideration |
ChangeInFairValueOfAcquisitionrelatedContingentConsideration
|
- | USD | 1 Quarter |
| Change in fair value of acquisition-related contingent consideration |
ChangeInFairValueOfAcquisitionrelatedContingentConsideration
|
$1.96M | USD | 3 Qtrs |
| Change in fair value of acquisition-related contingent consideration |
ChangeInFairValueOfAcquisitionrelatedContingentConsideration
|
$-147.00K | USD | 3 Qtrs |
| Change in fair value of acquisition-related contingent consideration |
ChangeInFairValueOfAcquisitionrelatedContingentConsideration
|
$174.00K | USD | 1 Quarter |
| Loan discount amortization and fee accretion |
AmortizationOfDeferredLoanOriginationFeesNet
|
$2.02M | USD | 3 Qtrs |
| Loan discount amortization and fee accretion |
AmortizationOfDeferredLoanOriginationFeesNet
|
$1.60M | USD | 3 Qtrs |
| Interest paid-in-kind |
PaidInKindInterest
|
$2.37M | USD | 3 Qtrs |
| Interest paid-in-kind |
PaidInKindInterest
|
$698.00K | USD | 3 Qtrs |
| Stock-based compensation |
ShareBasedCompensation
|
$549.00K | USD | 3 Qtrs |
| Stock-based compensation |
ShareBasedCompensation
|
$177.00K | USD | 1 Quarter |
| Stock-based compensation |
ShareBasedCompensation
|
$556.00K | USD | 3 Qtrs |
| Stock-based compensation |
ShareBasedCompensation
|
$187.00K | USD | 1 Quarter |
| Stock-based compensation |
ShareBasedCompensation
|
$192.00K | USD | 1 Quarter |
| Stock-based compensation |
ShareBasedCompensation
|
$187.00K | USD | 1 Quarter |
| Stock-based compensation |
ShareBasedCompensation
|
$179.00K | USD | 1 Quarter |
| Stock-based compensation |
ShareBasedCompensation
|
$183.00K | USD | 1 Quarter |
| Depreciation and amortization expense |
DepreciationDepletionAndAmortization
|
$3.31M | USD | 3 Qtrs |
| Depreciation and amortization expense |
DepreciationDepletionAndAmortization
|
$9.63M | USD | 3 Qtrs |
| Interest and accounts receivable |
IncreaseDecreaseInInterestAndDividendsReceivable
|
$-2.05M | USD | 3 Qtrs |
| Interest and accounts receivable |
IncreaseDecreaseInInterestAndDividendsReceivable
|
$-343.00K | USD | 3 Qtrs |
| Other assets |
IncreaseDecreaseInOtherOperatingAssets
|
$371.00K | USD | 3 Qtrs |
| Other assets |
IncreaseDecreaseInOtherOperatingAssets
|
$819.00K | USD | 3 Qtrs |
| Accounts payable and other liabilities |
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
$1.43M | USD | 3 Qtrs |
| Accounts payable and other liabilities |
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
$542.00K | USD | 3 Qtrs |
| Net cash provided by operating activities |
NetCashProvidedByUsedInOperatingActivities
|
$23.07M | USD | 3 Qtrs |
| Net cash provided by operating activities |
NetCashProvidedByUsedInOperatingActivities
|
$9.21M | USD | 3 Qtrs |
| Investment in finance receivables |
PaymentsToAcquireFinanceReceivables
|
$20.10M | USD | 3 Qtrs |
| Investment in finance receivables |
PaymentsToAcquireFinanceReceivables
|
$12.46M | USD | 3 Qtrs |
| Repayment of finance receivables |
ProceedsRepaymentOfFinanceReceivables
|
$31.16M | USD | 3 Qtrs |
| Repayment of finance receivables |
ProceedsRepaymentOfFinanceReceivables
|
$5.93M | USD | 3 Qtrs |
| Corporate debt securities principal payment |
MarketableInvestmentPrincipalPayment
|
$49.00K | USD | 3 Qtrs |
| Corporate debt securities principal payment |
MarketableInvestmentPrincipalPayment
|
$43.00K | USD | 3 Qtrs |
| Purchases of property and equipment |
PaymentsToAcquirePropertyPlantAndEquipment
|
$2.35M | USD | 3 Qtrs |
| Purchases of property and equipment |
PaymentsToAcquirePropertyPlantAndEquipment
|
$877.00K | USD | 3 Qtrs |
| Other |
PaymentsForProceedsFromOtherInvestingActivities
|
$-164.00K | USD | 3 Qtrs |
| Other |
PaymentsForProceedsFromOtherInvestingActivities
|
$220.00K | USD | 3 Qtrs |
| Net cash provided by (used in) investing activities |
NetCashProvidedByUsedInInvestingActivities
|
$-9.05M | USD | 3 Qtrs |
| Net cash provided by (used in) investing activities |
NetCashProvidedByUsedInInvestingActivities
|
$10.39M | USD | 3 Qtrs |
| Net (payments on) proceeds from credit facility |
ProceedsFromRepaymentsOfLinesOfCredit
|
- | USD | 3 Qtrs |
| Net (payments on) proceeds from credit facility |
ProceedsFromRepaymentsOfLinesOfCredit
|
$-11.75M | USD | 3 Qtrs |
| Payment of acquisition-related contingent consideration |
PaymentForContingentConsiderationLiabilityFinancingActivities
|
- | USD | 3 Qtrs |
| Payment of acquisition-related contingent consideration |
PaymentForContingentConsiderationLiabilityFinancingActivities
|
$6.08M | USD | 3 Qtrs |
| Repurchases of common stock, including fees and expenses |
PaymentsForRepurchaseOfCommonStock
|
- | USD | 3 Qtrs |
| Repurchases of common stock, including fees and expenses |
PaymentsForRepurchaseOfCommonStock
|
$2.00M | USD | 3 Qtrs |
| Net cash used in financing activities |
NetCashProvidedByUsedInFinancingActivities
|
$-2.00M | USD | 3 Qtrs |
| Net cash used in financing activities |
NetCashProvidedByUsedInFinancingActivities
|
$-17.83M | USD | 3 Qtrs |
| Net increase in cash and cash equivalents |
CashAndCashEquivalentsPeriodIncreaseDecrease
|
$-1.84M | USD | 3 Qtrs |
| Net increase in cash and cash equivalents |
CashAndCashEquivalentsPeriodIncreaseDecrease
|
$15.63M | USD | 3 Qtrs |
| Cash and cash equivalents at beginning of period |
CashAndCashEquivalentsAtCarryingValue
|
$9.31M | USD | Point-in-time |
| Cash and cash equivalents at beginning of period |
CashAndCashEquivalentsAtCarryingValue
|
$3.01M | USD | Point-in-time |
| Cash and cash equivalents at beginning of period |
CashAndCashEquivalentsAtCarryingValue
|
$11.16M | USD | Point-in-time |
| Cash and cash equivalents at beginning of period |
CashAndCashEquivalentsAtCarryingValue
|
$18.64M | USD | Point-in-time |
| Cash and cash equivalents at end of period |
CashAndCashEquivalentsAtCarryingValue
|
$9.31M | USD | Point-in-time |
| Cash and cash equivalents at end of period |
CashAndCashEquivalentsAtCarryingValue
|
$3.01M | USD | Point-in-time |
| Cash and cash equivalents at end of period |
CashAndCashEquivalentsAtCarryingValue
|
$11.16M | USD | Point-in-time |
| Cash and cash equivalents at end of period |
CashAndCashEquivalentsAtCarryingValue
|
$18.64M | USD | Point-in-time |
Stockholders Equity
42 line items
| Line Item | Tag | Value | Unit | Period |
|---|---|---|---|---|
| Balances at December 31, 2019 |
StockholdersEquity
|
$240.51M | USD | Point-in-time |
| Balances at December 31, 2019 |
StockholdersEquity
|
$258.24M | USD | Point-in-time |
| Balances at December 31, 2019 |
StockholdersEquity
|
$232.08M | USD | Point-in-time |
| Balances at December 31, 2019 |
StockholdersEquity
|
$260.67M | USD | Point-in-time |
| Balances at December 31, 2019 |
StockholdersEquity
|
$235.70M | USD | Point-in-time |
| Balances at December 31, 2019 |
StockholdersEquity
|
$244.08M | USD | Point-in-time |
| Balances at December 31, 2019 |
StockholdersEquity
|
$232.00M | USD | Point-in-time |
| Balances at December 31, 2019 |
StockholdersEquity
|
$236.53M | USD | Point-in-time |
| Stock-based compensation |
ShareBasedCompensation
|
$549.00K | USD | 3 Qtrs |
| Stock-based compensation |
ShareBasedCompensation
|
$177.00K | USD | 1 Quarter |
| Stock-based compensation |
ShareBasedCompensation
|
$556.00K | USD | 3 Qtrs |
| Stock-based compensation |
ShareBasedCompensation
|
$187.00K | USD | 1 Quarter |
| Stock-based compensation |
ShareBasedCompensation
|
$192.00K | USD | 1 Quarter |
| Stock-based compensation |
ShareBasedCompensation
|
$187.00K | USD | 1 Quarter |
| Stock-based compensation |
ShareBasedCompensation
|
$179.00K | USD | 1 Quarter |
| Stock-based compensation |
ShareBasedCompensation
|
$183.00K | USD | 1 Quarter |
| Issuance of common stock |
StockIssuedDuringPeriodValueNewIssues
|
- | USD | 1 Quarter |
| Issuance of common stock |
StockIssuedDuringPeriodValueNewIssues
|
- | USD | 1 Quarter |
| Issuance of common stock |
StockIssuedDuringPeriodValueNewIssues
|
- | USD | 1 Quarter |
| Issuance of common stock |
StockIssuedDuringPeriodValueNewIssues
|
- | USD | 1 Quarter |
| Issuance of common stock |
StockIssuedDuringPeriodValueNewIssues
|
- | USD | 1 Quarter |
| Issuance of common stock |
StockIssuedDuringPeriodValueNewIssues
|
- | USD | 1 Quarter |
| Net income |
ProfitLoss
|
$13.97M | USD | 1 Quarter |
| Net income |
ProfitLoss
|
$2.24M | USD | 1 Quarter |
| Net income |
ProfitLoss
|
$558.00K | USD | 3 Qtrs |
| Net income |
ProfitLoss
|
$-4.66M | USD | 1 Quarter |
| Net income |
ProfitLoss
|
$876.00K | USD | 1 Quarter |
| Net income |
ProfitLoss
|
$3.39M | USD | 1 Quarter |
| Net income |
ProfitLoss
|
$19.60M | USD | 3 Qtrs |
| Net income |
ProfitLoss
|
$4.34M | USD | 1 Quarter |
| Balances at September 30, 2020 |
StockholdersEquity
|
$240.51M | USD | Point-in-time |
| Balances at September 30, 2020 |
StockholdersEquity
|
$258.24M | USD | Point-in-time |
| Balances at September 30, 2020 |
StockholdersEquity
|
$232.08M | USD | Point-in-time |
| Balances at September 30, 2020 |
StockholdersEquity
|
$260.67M | USD | Point-in-time |
| Balances at September 30, 2020 |
StockholdersEquity
|
$235.70M | USD | Point-in-time |
| Balances at September 30, 2020 |
StockholdersEquity
|
$244.08M | USD | Point-in-time |
| Balances at September 30, 2020 |
StockholdersEquity
|
$232.00M | USD | Point-in-time |
| Balances at September 30, 2020 |
StockholdersEquity
|
$236.53M | USD | Point-in-time |
| Repurchases of common stock in open market |
StockRepurchasedDuringPeriodValue
|
$62.00K | USD | 1 Quarter |
| Repurchases of common stock in open market |
StockRepurchasedDuringPeriodValue
|
$1.03M | USD | 1 Quarter |
| Repurchases of common stock in open market |
StockRepurchasedDuringPeriodValue
|
$903.00K | USD | 1 Quarter |
| Issuance of common stock in lieu of payment of employee cash bonuses |
StockIssuedDuringPeriodValueEmployeeBenefitPlan
|
$60.00K | USD | 1 Quarter |
Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.